Sep 24, 2026 9:46 PM
Morgan Cheatham and Najat Khan bridge the gap between medicine and information science, revealing how clinical data and strategic AI integration are redefining biotech’s path to impact.
In our newest episode of TechBio Talks, we explore how AI and clinical data are converging to reshape the future of medicine.
CEO of Recursion, Najat Khan, PhD talks with Dr. Morgan Cheatham, Partner and Head of Healthcare and Life Sciences at Breyer Capital. As a physician, medical geneticist, and investor, Morgan brings a unique perspective, having spent nearly a decade backing category-defining companies spanning diagnostics, therapeutics, and care delivery.
We unpack:
🚀 How AI is reshaping the fundamentals of biotech value creation
💊 Why “modality market fit” is crucial for matching treatments to patient tolerance
🔬 Closing the loop between the wet lab, dry lab, and the clinic
🧬 Recasting medicine as an information science to close the gap between discovery and care
Listen and follow on:
Comments
Powered by RoundtableBuilt on infrastructure designed for real-time media. Learn more at RTB.io.© Roundtable 2026. By using this site you agree to the Terms of Use and Privacy Policy